Here, we passively immunized a well-characterized synucleinopathy mouse model, the Prnp-SNCA*A53T model, which has been studied extensively and shown to develop insoluble α-synuclein aggregates, α-synuclein oligomers and hyperphosphorylated tau [26, 64–66]. This evidence concerns the gene MAPT and synucleinopathy.